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ABSTRACT 
Aim: To determine the excess risk of all-cause and cardiovascular mortality in older people with elevated 
liver enzymes (alanine transaminase, ALT and gamma glutamyltransferase, GGT).  
Methods: We utilized data from a large, prospective, population based study of 2,061 people aged 50-
99 years with linkage to a national death registry.  Participants were categorized as having elevated liver 
enzymes using standard thresholds (for males, GGT >51 and ALT >40 IU/L, and GGT >33 and ALT >31 
IU/L for females). Adjusted Cox proportional hazards models assessed the association of elevated liver 
enzymes and mortality with long duration follow up.  
Results: Over a median follow up of 10 years (20,145 person years), 701 people died, including 203 
(34%) from cardiovascular disease. Cox regression  models adjusted for sex, age, smoking and alcohol 
intake indicated that people with elevated liver enzymes had an increased risk of all-cause mortality that 
was modified by age (test for interaction p=0.01). Age-stratified analyses demonstrated no increased 
risk at younger ages (age ≤ 59 years, H.R. 0.46  95% confidence interval 0.06-3.49), but increased risk 
with age; age 60-69, H.R. 1.05 (0.53-2.07), age 70-79 years, H.R. 1.54 (0.81-2.93), and age ≥ 80 years, 
H.R. 3.53 (1.55-8.04). Similarly, the risk of cardiovascular mortality with elevated liver enzymes was also 
modified by, and increased with age (test for interaction p=0.02); age 70-79, H.R. 3.15 (1.37-7.23), age ≥ 
80, H.R. 6.86 (2.44-19.30).  
Conclusion: In community dwelling elderly persons, an elevation in both ALT and GGT are associated 
with an excess risk of all-cause and cardiovascular mortality which increases with age.  
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Introduction  
Elevations in alanine transaminase (ALT) and gamma glutamyltransferase (GGT) are now recognised as 
robust markers of impaired metabolic health. ALT is an enzyme found predominantly in hepatocytes and 
is normally present in serum at low levels. However, during hepatocyte injury, levels of ALT increase 
substantially and are a sensitive and reliable marker of hepatic inflammation(1).  GGT is less specific 
than ALT for liver disease, however sustained elevations in GGT in association with ALT indicate hepatic 
inflammation; the commonest cause is nonalcoholic fatty liver disease (NAFLD)(2). Cross sectional 
studies have previously indicated an association between elevated liver enzymes above standard 
laboratory reference ranges, and cardiometabolic disorders including diabetes(3-5), and these 
associations were further explored in longitudinal studies, where meta-analyses suggest that an 
elevation in either ALT or GGT reliably predict incident diabetes(6, 7), metabolic syndrome(8) and all-
cause mortality(9, 10). Current literature however, has only studied mortality associations for elevated 
liver enzymes in isolation, and the association between elevations in both ALT and GGT with mortality 
outcomes is unknown.   
 
In addition, age may influence the association with mortality. Current evidence suggests that the 
mortality risk associated with elevated GGT is highest in middle age(11-14), however these studies have 
enrolled predominantly young to middle aged persons (aged 25-64 years) and there is scant data on the 
association in older people. Two single studies in exclusively elderly populations with mean age of 70 
years have shown a positive linear relationship for GGT and all-cause and cardiovascular mortality(15), 
however the association of ALT and all-cause mortality remains unclear (16).  
 
In this prospective cohort study, we aimed to examine the association between elevated ALT and GGT 
and all-cause and cardiovascular mortality in middle aged and older, community dwelling individuals. 
 
METHODS 
Study design and population 
The Blue Mountains Eye Study (BMES) is a prospective, population based cohort study of vision and 
other health outcomes in people aged 50 years of age and older in an urban, white Caucasian 
population west of Sydney, Australia. The survey was conducted among residents of two adjacent 
postcodes, chosen because they are geographically well defined and have a stable, homogeneous 
population.  The methods have been described in detail elsewhere(17). Briefly, in 1992, door knocking of 
each household in the area was undertaken to identify and invite all permanent residents born before 
January 1, 1943; at completion, this census differed from the Australian Census performed 3 months 
earlier by only 6 people. At study commencement, 4433 eligible residents were invited to participate 
and 3654 accepted (82.4% participation rate) and underwent clinical interview but blood tests were not 
collected at this time. In 1997, the study included 2335 individuals who agreed to re-interview and 
formed the baseline cohort of our study. These individuals underwent a structured questionnaire 
administered by trained interviewers who recorded demographic characteristics, height, weight and 
blood pressure. Fasting blood samples were collected for 2061 consenting people. Study follow-up 
ended in December 2007 when record linkage was performed. The study was approved by the 
University of Sydney and Sydney West Area Health Service Human Research Ethics Committee and 
written informed consent was obtained from all participants. 
 
Blood collection 
 
Fasting blood specimens were collected, centrifuged on site and sent within 4 hours to a tertiary level 
hospital for analysis using commercial kits on an automated analyzer (OCD Fusion 5.1; Ortho Clinical).  
The coefficient of variation (CV) for repeated measurements in these samples was < 4% for ALT and < 
2·8% for GGT. Serum lipids including triglycerides were measured on a Reflotron reflectance 
photometric analyzer (Boehringer Mannheim Diagnostics; currently, Roche Diagnostics), with CV for 
triglycerides of 1·4%. 
 
Definition of elevated liver enzymes 
 
We used a sex-specific threshold for elevated ALT and GGT in accordance with laboratory reference 
ranges and consistent with the threshold used in similar studies  (for males, GGT ≥ 51 and ALT ≥ 40, and 
for females GGT ≥ 33 and ALT ≥ 30)(18). Although a lower threshold for a statistically normal level of ALT 
has been proposed in cross sectional studies(19), there are currently no data on which threshold 
predicts long term morbidity and mortality, therefore a more conservative threshold was used. 
 
Ascertainment of outcome (mortality status) 
The primary outcomes were all-cause and cause specific (cardiovascular) mortality. To identify those 
who had died during follow up, record linkage with Australian National Death Index data until December 
2007 was undertaken. Causes of death were collected from death certificates completed by the doctor 
in attendance, coroner or medical examiner, and total and cause-specific mortality were recorded using 
the International Classification of Diseases, Ninth Revision (ICD-9, codes for cardiovascular mortality: 
(410.0-9, 411.0-8, 412, and 414.0-9). The Australian National Death Index data has high sensitivity and 
specificity for all-cause mortality (93.7% and 100% respectively) and cardiovascular mortality (92.5% and 
89.6% respectively)(20). 
 
Assessment of other variables 
Blood pressure was measured with a calibrated mercury sphygmomanometer.  Participants were 
recorded as having hypertension if blood pressure readings exceeded systolic blood pressure of ≥140 
mmHg and diastolic blood pressure of ≥80mmHg, or if they reported the use of anti-hypertensive 
medication. Participants were considered to have diabetes if they had self-reported doctor diagnosis of 
diabetes, received treatment in the past or currently, or had a fasting serum glucose > 7.0 mmol/L.  Self-
reported history of previous myocardial infarctions, previous or current regular smoking, and current 
alcohol intake (graded as none, 1-2 standard drinks/day, or 3 or more) were recorded. Body mass index 
(BMI) was calculated as weight/height2 (kg/m2).  
 
Statistical analysis  
Baseline characteristics were summarized using frequency tables for categorical variables and quartiles, 
medians, means and percentiles for continuous variables. Cohorts with elevated or normal–range liver 
enzymes were compared using X2 and t-test statistics for categorical and continuous variables 
respectively. Distribution of exposure, outcome and explanatory variables was assessed graphically, and 
log transformation of biochemical variables was performed for variables where the distribution was 
positively skewed. For survival analyses, baseline measurements were considered as the start of 
biochemical assessment (1997) and follow up continued to date of death or upon censoring (December 
31, 2007). 
 Univariate and multivariate models 
For univariate analyses, we used log rank tests to assess the association of survival with the following 
categorical explanatory variables:  sex, smoking status, diabetes, hypertension, previous myocardial 
infarcts and alcohol intake, and the following continuous explanatory variables: age, body mass index 
(kg/m2), total cholesterol (mmol/L) and triglycerides (mmol/L). Univariate Cox proportional hazards 
models were constructed to estimate the size and direction of hazard ratios for individual variables, and 
variables with p <0.25 in unadjusted analyses, or variables that were considered potential confounders 
of the relationship with mortality or cardiovascular mortality such as cardiovascular risk factors 
(including diabetes, hypertension, BMI, total cholesterol and triglycerides), were included in baseline 
multivariate models. 
 
Multivariate Cox proportional hazards models were refined using manual backwards elimination until 
only variables with p<0.05 remained. All models were adjusted for alcohol given its known effect on liver 
enzymes. Effect modification between elevated liver enzymes and (i) age and (ii) sex was assessed using 
two-way interaction terms and tested in the full model. Linearity of variables was checked by tests for 
trend and by categorizing into quartiles and plotting the estimated model coefficients against the 
midpoint of each quartile. Where linearity was uncertain, further assessment using transformation of 
variables was performed. Linearity of age was assessed by tests for trend, graphical assessment and 
transformation, and was determined to be linear. To determine if the proportional hazards assumption 
was met, we tested log (time) dependent covariates sequentially in the model for statistical significance, 
followed by plotting of Schoenfeld residuals for each variable(21), and visual assessment was 
undertaken to determine any substantial deviation from the centre. No variables showed evidence of 
departure from the proportional hazards assumption. Statistical analyses were performed using SAS 9.3 
(SAS institute, Cary, NC). 
 
RESULTS 
Baseline cohort 
At the first assessment in 1997, there were 2,553 people with data on age, gender and relevant co-
morbidities and of these, 2061 (81%) had blood tests available and were used as the baseline cohort 
(Figure 1). Median follow up was 9.9 years (range 0.2 – 10.9 years), resulting in 20,145 person-years of 
follow up.  Cumulative mortality was 34% (701 deaths), of which 203 (29% of total deaths) were due to 
cardiovascular disease. 
 
Characteristics of participants  
Participant characteristics are shown in Table 1. The prevalence of elevated ALT and GGT above the 
thresholds of GGT ≥ 51 and ALT ≥ 40 for males, and GGT ≥ 33 and ALT ≥ 30 for females was 5.2% 
(n=108). The cohort with elevated liver enzymes were more likely to be diabetic (19% vs. 7%, p<0.001), 
to have a higher mean BMI (29.8 kg/m2 vs. 26.7kg/m2, p<0.001) and have higher fasting triglyceride 
levels (1.64 mmol/L vs. 1.32 mmol/L, p<0.001).  The proportion of participants who were smokers, 
hypertensive and had a history of myocardial infarction were similar in both groups.   
 
Elevated ALT/GGT and all-cause mortality  
In model building, we tested for significant interactions of elevated liver enzymes with age or sex, and 
found that the excess risk of mortality with elevated enzymes was not constant, but varied according to 
baseline age. The hazard ratio for the interaction was positive (H.R. 1.06 95% C.I. 1.01-1.12, p=0.01), 
indicating that the hazard increased by a multiple of 1.06 for each additional year of age (Table 2), with 
the plotted hazard curve indicating increasing risk with age (Figure 2). To explore the effect of age, 
stratified models using age in decades of ≤ 59 years, 60-69, 70-79 and ≥ 80 years (Table 3) were 
developed, adjusted for significant covariates of sex, smoking status and alcohol. Age-specific estimates 
for the excess risk and 95% confidence intervals were derived, although confidence intervals are 
imprecise given they are based on only a subset of the data. Consistent with the results of the main 
model, the estimated hazard ratio for those with elevated liver enzymes increased with age (H.R. 1.05 
(0.53-2.07) for those aged 60-69 years, H.R. 1.54 (0.81-2.93) for 70-79 year olds and H.R. 3.53 (1.55-
8.04) for those aged ≥ 80 years (Table 3). There was no evidence of an increase in mortality with 
elevated liver enzymes among the youngest age group (H.R. 0.46 95% CI 0.06-3.49, for those aged ≤ 59 
years). The stratum specific estimates, when plotted against the median age for that stratum, agree 
closely with the estimated hazard ratios derived from the main model as displayed in Figure 2.  
 
Elevated ALT/GGT and cardiovascular mortality  
During model building for cardiovascular mortality, there was also evidence of age modifying the risk of 
elevated liver enzymes (test for interaction H.R. 1.10, 95% C.I. 1.02-1.20, p=0.02), indicating that the 
hazard increased by a multiple of 1.10 for each additional year of age. To explore the effect of age on 
cardiovascular mortality, stratified models using age in decades (≤ 59 years, 60-69, 70-79 and ≥ 80 years) 
were developed and adjusted for significant covariates of sex and alcohol (Table 3). Age-stratified 
models did not show increased risk in the youngest age group (for age 60-69 years, H.R. 0.50 (0.07-3.70), 
however increased risk was seen in those aged 70-79 years, with a H.R. 3.15 (1.37-7.23) and for those 
≥80  years or older, H.R. 6.86 (2.44-19.30) (Table 3). The hazard curve is shown in Figure 2, and if 
stratum specific estimates are plotted against the median age in that stratum, the estimates are closely 
approximated and indicate that the excess risk for cardiovascular mortality begins approximately at age 
66 years. The slope of the hazard curve for cardiovascular mortality is steeper than that for all-cause 
mortality, reflecting the larger interaction estimate. 
 
DISCUSSION 
 
These data, from a large prospective cohort study of community dwelling individuals, suggest that 
middle aged and older persons with elevations in both ALT and GGT have an excess risk of all-cause and 
cardiovascular mortality that is age-dependent. To explore the effect of age, we stratified the cohort by 
age per decade and found an increasing risk of all-cause mortality starting at age 60-69 and increasing 
steadily by decade. While the hazard ratios increased per decade, a statistically significant difference 
was seen only in the 80 years and older group, reflecting the loss of statistical power that occurs when 
stratifying into small groups. The hazard curve, plotted from estimated risk per individual year using the 
model equation, similarly demonstrates increasing risk with age. Regarding cardiovascular mortality risk, 
a significant increase was seen for those aged 70 years and older and also increased with age. As alcohol 
is a potential confounder of the relationship between elevated liver enzymes and mortality, it was 
adjusted for in all analyses but the risk remained independent. 
 
While there are no previous studies of mortality risk in people with elevation in both liver enzymes with 
which we can compare, these data concur with previous findings of increased mortality with elevation of 
either GGT or ALT in isolation. Using the same GGT cutoff in a study of 2634 elderly people, Loomba et al 
found an increase in mortality, with an overall hazard ratio of 1.55 and 1.51 for all-cause and 
cardiovascular mortality respectively(15), similar to our finding of a hazard ratio for persons aged 70-79 
(H.R. 1.54). As this study stratified by age, we found a lower risk for younger persons (HR 1.05 for those 
aged 60-69 years) and higher for older persons (H.R. 3.53 for those aged 80 and older). A second study 
in an elderly population of 5,186 people found a similar association of GGT alone and mortality that was 
linear, and no interaction with age was seen(16). In meta analyses of GGT and all-cause mortality of 
persons of all ages, there is a relative risk for those in the top third of GGT levels of 1.60 (95% CI 1.42-
1.80)(10). Meta-analyses of GGT and cardiovascular mortality show a relationship of similar magnitude 
(9, 22).  
 
While the relationship between GGT and mortality seems linear, the relationship between elevated ALT 
alone and mortality appears more complex. A population based study in people aged > 55 years found a 
J-shaped relationship, where people with ALT levels < 12 or > 35 IU/L had the highest mortality(16); 
these findings were replicated in a another, smaller study of people aged over 70  where mortality was 
highest with serum ALT < 12 IU/L(23). Data from a meta-analysis of ALT and all-cause mortality also 
found a J-shaped association, with higher mortality at serum ALT < 10 IU/L or > 17 IU/L, but no excess 
risk in between(10). For ALT and cardiovascular mortality, data is conflicting and difficult to interpret, 
with an inverse relationship seen in some studies(22, 24), while others suggest a positive linear 
relationship(25). As we examined only persons with elevated ALT in this study, we cannot comment on 
mortality risk for those with very low ALT. However, the bulk of currently available data suggests 
increased mortality risk with elevation of either enzyme alone, and our study extends these findings by 
demonstrating that increased risk also occurs with elevation of both enzymes, particularly in the very 
elderly. 
 
The underlying mechanisms for why people with elevated liver enzymes may experience increased 
mortality are suggested from human and experimental data. GGT metabolizes glutathione, an 
intracellular antioxidant(26). GGT is upregulated in states of oxidative stress(27) and may influence 
oxidative events within atherosclerotic plaques causing plaque instability and rupture(28). Elevations in 
serum GGT levels predict an increased risk of incident metabolic syndrome and diabetes(6), although 
whether GGT has a causal role is unable to be determined on the basis of observational data. ALT is an 
enzyme specific for liver inflammation but abundant evidence also supports a predictive role for ALT 
with metabolic syndrome(8) and diabetes(6, 29).  Moreover, it has been assumed that elevated ALT is a -
consequence of insulin resistance but emerging data proposes that ALT may precede the development 
of metabolic disorders(30), and further work to disentangle this relationship is awaited.  
 
From a clinical perspective, these data suggest that middle aged and older individuals from the general 
community who have elevated GGT and ALT have an increased risk of cardiovascular mortality. The 
presence of elevated liver enzymes should prompt clinical assessment and treatment of modifiable 
cardiovascular risk factors using standard, evidence based guidelines. From a research perspective, 
these data raise the possibility that ALT and/or GGT may add incremental value to risk prediction scores. 
A recent study that has assessed prognostic value of GGT when added to the Framingham risk prediction 
model found a small but significant improvement in predictive accuracy for cardiovascular disease(31), 
however other studies have found no incremental benefit with addition of GGT or ALT(14, 32). Given 
that cardiovascular death remains the single largest cause of death globally, further work in this area 
would be informative.  
 
Our choice of threshold for elevated liver enzymes deserves mention. As there is no accepted level of 
what constitutes normal or abnormal liver biochemistry, we chose gender specific cutoffs of ALT of 30 
IU/L  for women and 40 IU/L for men based on other large epidemiological studies to allow 
comparison(33), consistent with lab reference ranges, and supported by the single study that has 
longitudinally assessed ALT and all-cause mortality risk. That study found that a cutoff of 30 IU/L 
displayed the best predictive value according to receiver operating curve characteristics(34). 
 
This study has a number of strengths,  including near complete capture of a homogeneous population 
that differed from the national census by only 6 people, an 82.4% initial response rate, high cumulative 
mortality that increases the study’s power, and long duration follow up at a median of 10 years. The 
dataset had few missing baseline data and included detailed information on confounders. All blood 
samples were performed fasting and were analysed within 4 hours of extraction, minimizing lab-related 
measurement error. Furthermore, measurement error in the outcome variable of cardiovascular 
mortality is likely to be small, given that prior research suggests a high degree of accuracy for correct 
classification of cardiovascular mortality in this dataset(20). There are a number of potential limitations 
to our study. Causality cannot be determined on the basis of observational data, however high quality, 
long duration prospective cohort studies are the best study type to address associations with mortality. 
Selection bias may also have influenced our results since not all participants agreed to interview and 
blood tests, however the loss to follow up which may also contribute to selection bias was low. The 
prevalence of viral hepatitis as a cause for elevated ALT in this Caucasian population is very low (less 
than 1%), and even when excluded from demographically similar NHANES-III cohorts, people with viral 
hepatitis have only accounted for 0.4% of the population(35). Finally, although non-alcoholic fatty liver 
disease is a common cause of elevated ALT and GGT, we were not able to separate those with NAFLD 
(diagnosed by liver biopsy or imaging technique) and elevated liver enzymes, and examine mortality 
outcomes in this subgroup, and this is an important question for future research. 
 
Conclusion 
In conclusion, these data from 20,145 person years of follow up, indicate that middle aged and older 
persons with elevated GGT and ALT have an excess risk of all-cause and cardiovascular mortality that 
increases with age. These individuals should be targeted for management of metabolic risk factors. 
Further studies in persons with elevations of both ALT and GGT are desirable to compare to our findings. 
In addition, research to establish a threshold for liver enzymes above which a significantly increased risk 
is conferred, would be clinically useful.   
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FIGURE LEGENDS 
 
Figure 1. Study cohort 
 
 
Figure 2. Hazard curve of excess risk of all cause and cardiovascular mortality in those with elevated 
enzymes compared to those with normal enzymes, according to age. 
 
Table 1: Participant characteristics at baseline for overall cohort and in those with and without 
elevated enzymes. 
 
 
 
 
Overall cohort at 
baseline (n=2061) 
 
People without 
elevated 
ALT/GGT  
(n=1953) 
 
 
People with 
elevated 
ALT/GGT 
(n=108) 
 
 
P value 
Sex (females) 
 
Age (median, IQR)* 
58% vs.42% 
 
69 (63-75) 
 
57% vs. 43% 
 
70 (63-76) 
67% vs. 32% 
 
65 (60-71) 
 
0.04 
 
<0.001 
Comorbidities (N,%)     
Smoking 
Hypertension 
Diabetes  
 1016 (49) 
 757 (37) 
 171 (8) 
957 (49) 
723 (37) 
137 (7) 
63 (58) 
40 (37) 
21 (19) 
0.09 
0.96 
<0.001 
Previous myocardial infarct  
 
Anthropometry* 
BMI (kg/m2)  
  183 (9) 
 
 
26.8 (24.2-29.7) 
176 (9) 
 
 
26.7 (24.2-29.6) 
8 (7) 
 
 
29.8(26.7-32.4) 
0.38 
 
 
<0.001 
Table
 Alcohol consumption# (N, %)     
0  
1-2 
≥ 3 
 
Biochemistry* 
ALT (IU/ml) 
GGT (IU/ml) 
Fasting triglycerides (mmol/L) 
Fasting total cholesterol (mmol/L) 
553 (24) 
1427 (62) 
334 (14) 
 
 
     19 (15-26) 
22 (16-32) 
1.34 (0.98-1.83) 
 5.9 (5.2-6.6) 
24% 
62% 
14% 
 
 
19 (14-24) 
21 (16-29) 
1.32 (0.97-1.78) 
 5.9 (5.2-6.6) 
18% 
59% 
23% 
 
 
45 (38-60) 
69 (51-118) 
1.64 (1.2-2.4) 
6.05 (5.5-6.8) 
 
          0.02^ 
 
 
 
       <0.001 
<0.001 
<0.001 
0.07 
*median with 25th-75th centiles;# standard drinks of alcohol/day where 1 standard drink=10g alcohol.^ overall P value. 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Adjusted hazard ratios for all-cause and cardiovascular mortality for those with elevated 
GGT/ALT compared to those without elevated GGT/ALT. 
 All-cause mortality Cardiovascular mortality 
 
 Adjusted  Adjusted  
 HR (95% CI) 
 
HR (95% CI) 
 
Elevated GGT/ALT vs 
non-elevated# 
 
 1.26 (0.82-1.96) 1.29 (0.49-3.44) 
Age (per year)* 
 
 
1.05 (1.01- 1.11) 1.04 (0.95-1.13) 
Interaction 
(Elevated GGT/ALT 
×age) 
 
        1.06 (1.01 -1.12) 1.10 (1.02-1.20) 
Male sex 1.59 (1.35-1.87) 2.42(1.82-3.24) 
  
Smoking (previous 
or current) 
 
1.34 ( 1.14 -1.57) NA 
Alcohol (1-2 
standard drinks) vs 
none 
 
0.69 (0.58-0.82) 0.74 (0.55-1.01) 
Alcohol (≥3 standard 
drinks) vs none 
0.79 (0.61-1.03) 0.59 (0.35-0.99) 
#Age centred at the median age of 69 years, therefore this represents the hazard ratio for a 69 year old with elevated GGT/ALT. 
*The interaction term represents the multiplicative factor by which the hazard ratio increased for those with elevated GGT/ALT 
per additional year of age 
 
 
 
 
 
 
 
 
 Table 3. Adjusted* hazard ratios for all-cause and cardiovascular mortality for people with elevated 
GGT/ALT compared to those without elevated GGT/ALT, stratified by age in decades. 
 
Age 
(decade) 
Median Age 
(years) 
All-cause mortality Cardiovascular mortality 
 
  Adjusted Hazard Ratio (95% CI) Adjusted Hazard Ratio (95% CI) 
   
 
 
 
≤ 59     57  0.46 (0.06-3.49) N/A 
60-69  
70-79 
                64  
74  
1.05 (0.53-2.07) 
1.54 (0.81-2.93) 
0.50 (0.07-3.70) 
3.15 (1.37-7.23) 
≥ 80 83 3.53 (1.55-8.04) 6.86 (2.44-19.30) 
*Hazard ratios for all-cause mortality adjusted for age, sex, smoking and alcohol intake. Hazard ratios for cardiovascular 
mortality adjusted for age, sex and alcohol intake. 
 
 
 
 
 
Figure 1 Click here to download Figure Figure 1_ study cohort for JGM
tiff.tiff
Figure 2 Click here to download Figure Figure 2 ALT GGT hazard curve.tif 
  
 
Dr Martin H. Floch, MD 
Editor, Journal of Clinical Gastroenterology  
 
 
Dear Dr Floch, 
 
Thank you for considering our study “Elevated liver enzymes and mortality in older 
individuals: a prospective cohort study” for publication in Journal of Clinical 
Gastroenterology. 
 
Liver enzymes are a widely and frequently used diagnostic test, and there has been 
increasing interest in whether they may be useful as biomarkers of incident metabolic 
diseases and mortality. Elevations in GGT and ALT are associated with increased all-
cause mortality, with meta-analyses showing a positive, linear association particularly 
for GGT. However whether combinations of liver enzymes, such as elevations in both 
ALT and GGT, offer better predictive accuracy has not been studied. 
 
We utilized data from a large, prospective, population based study of older people 
(mean age 70 years) to assess the association between elevated enzymes and all-cause 
and cardiovascular mortality. We performed fully adjusted survival analyses using 
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baseline liver enzyme measurements, with linkage to national death registries and long 
duration (median 10 years) follow up. 
 
Our findings suggest that those with elevated enzymes at baseline have an increased 
risk of mortality at follow up, and the excess risk of mortality increases with age. The 
nature of the relationship appears to be J-Shaped, with excess, independent risk 
commencing in the decade 60-69 years. We also found the excess risk for cardiovascular 
mortality was higher than that for all-cause mortality. This information is useful at a 
clinical and population level, and provides novel data given that all existing studies have 
only looked at either enzyme in isolation, and in younger, lower risk populations. 
 
This study was approved by the University of Sydney and Sydney West Area Health 
Service Human Research Ethics Committee and written informed consent was obtained 
from all participants. We confirm that this manuscript has not been submitted 
elsewhere. 
 
Thank you for the opportunity to submit to Journal of Clinical Gastroenterology,  
 
Dr S Mahady on behalf of the co-author team. 
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